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Abstract
Introduction: Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with
unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in
the first intron of the C9orf72 gene represents the most common genetic cause of familial frontotemporal
dementia (FTD) and amyotrophic lateral sclerosis (ALS). Previous studies by immunohistochemistry with two
different anti-C9orf72 antibodies named sc-138763 and HPA023873 showed that C9orf72 is expressed chiefly in the
cytoplasm of neurons, and is concentrated in the synaptic terminals in the brains of FTD/ALS with or without
C9orf72 repeat expansion as well as those of controls. At present, a pathological role of C9orf72 in the process of
neurodegeneration remains unknown.
Methods: Using immunohistochemistry we studied C9orf72 expression in the frontal cortex and the hippocampus
of six Alzheimer’s disease (AD) and 13 control cases, including ALS, Parkinson’s disease, multiple system atrophy,
and non-neurological cases.
Results: The HPA023873 antibody showed a cross-reactivity to glial fibrillary acidic protein, and therefore stained
intensely reactive astrocytes in AD and non-AD brains. Both sc-138763 and HPA023873 antibodies labeled the
neuronal cytoplasm and the neuropil with variable intensities, and intensely stained a cluster of p62-negative,
UBQLN1-positive swollen neurites, which were distributed in the CA1 region and the molecular layer in the
hippocampus of both AD and non-AD brains. Most notably, both of these antibodies reacted strongly with
dystrophic neurites accumulated on senile plaques in AD brains.
Conclusion: These results suggest a general role of C9orf72 in the process of neurodegeneration in a range of
human neurodegenerative diseases.
Introduction
Chromosome 9 open reading frame 72 (C9orf72) is an
evolutionarily conserved protein with unknown function,
expressed in most tissues including the brain. Recent stu-
dies indicate that an expanded hexanucleotide GGGGCC
repeat located in the first intron of the C9orf72 gene
represents the most common genetic abnormality for
familial cases of frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS) with European ances-
try, both of which constitute an overlapping continuum of
a multisystem disorder affecting the central nervous sys-
tem (CNS) [1-4]. The patients with the C9orf72 repeat
expansion exhibit a clinical phenotype, characterized by an
earlier disease onset with bulbar involvement, the presence
of cognitive and behavioral impairment, psychosis, sym-
metrical frontotemporal atrophy, and reduced survival
time [5-15]. The C9orf72 mutation is inherited in an auto-
somal dominant manner with incomplete penetrance. In
contrast, the repeat expansion is found in less than 1% of
Alzheimer’s disease (AD) patients and normal subjects,
and is extremely rare in Japanese ALS patients [14,16-18].
The noncoding C9orf72 repeats, expanding from 700
to 1,600 copies, inhibit the expression of one alternatively
spliced transcript, and induce the formation of nuclear
RNA foci composed of the hexanucleotide repeat [1].
The RNA foci sequester RNA-binding proteins, leading
to aberrant mRNA splicing and processing of a set of
genes pivotal for neuronal function [19]. The brains of
FTD/ALS patients with the C9orf72 repeat expansion
show not only the classical pathology, characterized by
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neuronal loss and astroglial and microglial activation pro-
minent in the frontotemporal cortex, and degeneration of
motor neurons in the spinal cord, but also the TAR
DNA-binding protein-43 (TDP-43) pathology designated
type B and/or type A most evident in the hippocampus
[5-10]. Furthermore, numerous C9orf72-negative, TDP-
43-negative, p62-positive neuronal cytoplasmic and
nuclear inclusions are accumulated in the cerebellar
granular cell layer and the dentate gyrus of the hippo-
campus of the brains of FTD/ALS patients with C9orf72
mutations [8,20]. Importantly, a panel of missense muta-
tions is identified in the gene encoding p62, also known
as sequestosome 1, in familial and sporadic ALS patients,
supporting a key role for p62 in the pathogenesis of
FTD/ALS [21].
By immunohistochemistry with two different commer-
cially available anti-C9orf72 antibodies named sc-138763
and HPA023873, previous studies have shown that
C9orf72 is expressed chiefly in the cytoplasm of neurons,
presenting with varying immunoreactivities, and is highly
concentrated in synaptic terminals in the neuropil
[1,5-7,9,15]. Neuronal nuclei are largely devoid of
C9orf72. In contrast, different studies have shown that
C9orf72 is predominantly located in the nucleus of
human fibroblasts and mouse NSC-34 motor neuron
cells [2], and is expressed in both the cytoplasm and the
nucleus of SH-SY5Y human neuroblastoma cells [3]. The
discrepancy of subcellular location is attributable to dif-
ferences in the cell types examined and the uncharacter-
ized antibodies utilized. Importantly, no quantitative
differences are observed in the levels of C9orf72 expres-
sion in the brains between FTD/ALS patients with or
without C9orf72 repeat expansion and the controls,
where intracellular inclusions except for Pick bodies do
not express C9orf72 immunoreactivity [1-3,5-7,9,15]. On
the contrary, the levels of C9orf72 protein are reduced in
fibroblasts isolated from FTD/ALS patients with the
repeat expansion [2].
At present, the physiological and pathological roles of
C9orf72 in the CNS remain largely unknown, owing to a
lack of thorough knowledge on C9orf72 expression and
distribution in the human CNS. In the present study, we
characterized the specificity of two anti-C9orf72 antibodies
employed by previous studies. We found that the
HPA023873 antibody shows a substantial cross-reactivity
to glial fibrillary acidic protein (GFAP). We investigated
the expression of C9orf72 in the frontal cortex and the
hippocampus of six AD patients and 13 age-matched non-
AD subjects by immunohistochemistry. We found that
C9orf72 is expressed in dystrophic neurites accumulated
on senile plaques of AD brains and focally swollen neur-
ites distributed in the molecular layer in the hippocampus
of both AD and non-AD brains, suggesting a general role
of C9orf72 in the process of neurodegeneration.
Materials and methods
Human brain tissues
Serial sections of the frontal cortex and the hippocampus
10 μm thick were prepared from autopsied brains of six
sporadic AD patients, comprising three men and three
women with mean age 73 ± 9 years, and 13 non-AD
patients, comprising six men and seven women with
mean age 74 ± 8 years. The non-AD group included four
normal subjects who died of non-neurological causes,
three patients with sporadic Parkinson’s disease (PD),
four patients with sporadic ALS, and two patients with
sporadic multiple system atrophy (MSA). The demo-
graphic profiles of the cases examined are shown in
Table 1. All AD cases satisfied the Consortium to Estab-
lish a Registry for Alzheimer’s Disease criteria for diagno-
sis of definite AD [22], and they were categorized into
stage C of amyloid deposition and stage VI of neurofibril-
lary degeneration, following the Braak staging system
[23].
Autopsies on all subjects were performed at the
National Center Hospital, National Center of Neurology
and Psychiatry, Japan or at Kohnodai Hospital, National
Center for Global Health and Medicine, Japan. The
comprehensive examination of autopsied brains by three
established neuropathologists (KA, YS, TI) validated the
pathological diagnosis. Written informed consent was
obtained from all cases. The Ethics Committee of the
corresponding institutions approved the present study.
Immunohistochemistry
The primary antibodies utilized in the present study and
their working concentrations are presented in Table 2.
The brain tissues were fixed with 4% paraformaldehyde
and embedded in paraffin. After deparaffination, tissue
sections were heat-treated in 10 mM citrate sodium buf-
fer, pH 6.0 or pH 9.0, by autoclaving them at 125°C for
30 seconds in a temperature-controlled pressure chamber
(Dako, Tokyo, Japan). The tissue sections were incubated
at room temperature for 15 minutes with 3% hydrogen
peroxide-containing methanol to block the endogenous
peroxidase activity. For amyloid-beta immunolabeling,
the sections were exposed to formic acid at room tem-
perature for 5 minutes. They were incubated with PBS
containing 10% normal goat or rabbit serum at room
temperature for 15 minutes to block nonspecific staining.
Subsequently, they were incubated at 4°C overnight with
anti-human C9orf72 antibody raised against the peptide
spanning amino acid residues 165 to 215 (sc-138763;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with
anti-human C9orf72 antibody raised against the peptide
spanning amino acid residues 110 to 199 (HPA023873;
Sigma, St. Louis, MO, USA). In some experiments, the
serial tissue sections were incubated with anti-ubiquilin-1
(UBQLN1; PLIC1) antibody (sc-14652; Santa Cruz
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Biotechnology) or anti-ubiquilin-2 (UBQLN2; PLIC2)
antibody (sc-14658; Santa Cruz Biotechnology). The spe-
cificity of sc-14652 and sc-14658 was validated individu-
ally by western blot of the corresponding recombinant
proteins expressed in HEK293 cells. We verified that the
sc-14652 antibody does not label UBQLN2, while sc-
14658 does not react with UBQLN1. After washing with
PBS, the tissue sections were labeled at room tempera-
ture for 30 minutes with peroxidase-conjugated second-
ary antibodies (Nichirei, Tokyo, Japan), followed by
incubation with diaminobenzidine tetrahydrochloride
substrate (Vector, Burlingame, CA, USA). They were pro-
cessed for a counterstain with hematoxylin. For negative
controls, the primary antibody was omitted from the
reaction.
Double immunolabeling was performed according to the
methods described previously [24]. The tissue sections
were initially stained with anti-amyloid beta 11 to 28 anti-
body (12B2; Immunobiological Laboratory, Gunma,
Japan), anti-p62 antibody (610832; BD Biosciences,
San Jose, CA, USA), anti-ubiquitin antibody (sc-8017,
P4D1; Santa Cruz Biotechnology), anti-phospho-TDP-43
antibody (pS409/410; Cosomo Bio, Tokyo, Japan), or anti-
PHF-tau antibody (AT8; Thermo Scientific, Rockford, IL,
USA). The staining was followed by incubation with
alkaline phosphatase-conjugated secondary antibody
(Nichirei), and colorization with New Fuchsin substrate
(Nichirei). After inactivation of the antibodies by autoclav-
ing the sections, they were relabeled with anti-C9orf72
antibody sc-138763 or HPA023873, and then were incu-
bated with peroxidase-conjugated secondary antibodies,
colorized with diaminobenzidine tetrahydrochloride sub-
strate, and enhanced by exposure to diaminobenzidine
tetrahydrochloride enhancing solution (Vector).
RT-PCR analysis
[25]. Total cellular RNA was extracted using TRIZOL
(Invitrogen, Carlsbad, CA, USA). RNA treated with DNase
I was processed for cDNA synthesis using oligo(dT)20 pri-
mers and SuperScript II reverse transcriptase (Invitrogen).
cDNA was then amplified by PCR using HotStar Taq
DNA polymerase (Qiagen, Valencia, CA, USA) and a
Table 1 Demographic profile of the cases examined in the present study
Case IHC WB Age (years) Sex Cause of death Brain weight (g) Postmortem
interval (hours)
Braak staging (amyloid deposition/
neurofibrillary degeneration)
NC1 + + 88 F Acute myocardial infarction 1,130 1.4 A/II
NC2 + + 84 M Acute myocardial infarction 1,350 1.6 0/II
NC3 + + 77 M Lung cancer 1,060 3.9 A/II
NC4 + + 67 M Dissecting aortic aneurysm 1,400 4.8 A/I
AD1 + + 68 F Pneumonia 1,000 1.1 C/VI
AD2 + 56 M Pneumonia 1,230 14 C/VI
AD3 + + 59 M Pneumonia 1,220 10.5 C/VI
AD4 + + 72 M Pneumonia 1,240 8.1 C/VI
AD5 + + 82 F Lung cancer 1,090 4.5 C/VI
AD6 + + 77 F Pulmonary infarction 840 3 C/VI
AD7 + 70 M Respiratory failure by
aspiration
1,200 3.8 B/IV
AD8 + 80 M Pneumonia 1,060 8 C/VI
PD1 + 86 F Pneumonia 1,330 9.5 B/IV
PD2 + + 83 F Pneumonia 1,130 2.5 B/II
PD3 + + 76 F Respiratory failure by
aspiration
910 2.5 B/II
PD4 + 56 M Colon cancer 1,430 4 A/I
PD5 + 79 M Pneumonia 1,320 9.3 C/III
ALS1 + + 70 M Respiratory failure 1,480 10.5 0/0
ALS2 + + 75 F Respiratory failure 1,090 1.3 0/I
ALS3 + + 66 M Respiratory failure 1,560 3 0/I
ALS4 + + 61 F Respiratory failure 1,320 10 0/II
ALS5 + 61 M Respiratory failure 1,360 2.5 B/I
ALS6 + 74 M Respiratory failure 1,600 13 B/I
MSA1 + 73 F Pneumonia, septicemia 1,040 1.5 0/I
MSA2 + 66 F Pneumonia 1,090 12 A/I
The demographic profile of the cases processed for immunohistochemistry (IHC) and western blotting (WB) is shown with the case number, age, sex, cause of
death, brain weight, postmortem interval, and Braak Staging (amyloid deposition/neurofibrillary degeneration). AD, Alzheimer’s disease; ALS, amyotrophic lateral
sclerosis; F, female; M, male; MSA, multiple system atrophy; NC, non-neurological causes; PD, Parkinson’s disease.
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Table 2 Primary antibodies utilized for immunohistochemistry and western blot analysis
Antibody Supplier Code Origin Antigen utilized for raising antibodies Concentration used for IHC
(μg/ml)
Concentration used for WB
(μg/ml)
C9orf72 Santa Cruz Biotechnology (Santa
Cruz, CA, USA)
sc-138763 Rabbit Peptide spanning amino acid residues 165 to 215 of
human C9orf72
0.1 0.1
C9orf72 Sigma (St. Louis, MO, USA) HPA023873 Rabbit Peptide spanning amino acid residues 110 to 199 of
human C9orf72
0.72 0.1
UBQLN1 Santa Cruz Biotechnology sc-14652 Goat Peptide mapping within an internal region of human
UBQLN1
1 0.2









Mouse Human amyloid beta 11 to 28 peptide 1 NA
p62/
sequestosome 1
BD Biosciences (San Jose, CA, USA) 610832 Mouse Peptide spanning amino acid residues 257 to 437 of
human p62
1 NA
Ubiquitin Santa Cruz Biotechnology sc-8017
(P4D1)
Mouse Peptide spanning amino acid residues 1 to 76 of
bovine ubiquitin
0.2 NA
PHF-tau Thermo Scientific (Rockford, IL, USA) MN1020
(AT8)
Mouse Partially purified human PHF-tau 0.25 0.2
pS409/410 TDP-
43
Cosomo Bio (Tokyo, Japan) TIP-PTD-
M01
Mouse Phosphopeptide CMDSKpSpSGWGM Diluted at 1:500 NA
GFAP Nichirei (Tokyo, Japan) 422261
(GA5)
Mouse GFAP purified from swine spinal cord Prediluted Further diluted at 1:1,000
HSP60 (N-20) Santa Cruz Biotechnology sc-1052 Goat Peptide mapping in the N-terminus of human HSP60 NA 0.1

















panel of sense and antisense primer sets: 5’-ccttgatttaacag-
cagagggcga-3’ and 5’-tttccccacaccactgagctactt-3’ for a 210
bp product specific for C9orf72 isoform a; 5’-gaatggaagat-
cagggtcacag-3’ and 5’-gatggtatctgcttcatccagc-3’ for a
221 bp product specific for C9orf72 isoform b; and 5’-
ccatgttcgtcatgggtgtgaacca-3’ and 5’-gccagtagaggcagggat-
gatgttc-3’ for a 251 bp product of the G3PDH gene.
Vector construction
To study the specificity of anti-C9orf72 antibodies, the
full-length ORF of the human C9orf72 gene [GenBank:
NM_018325] or the human GFAP gene [GenBank:
NM_002055] was amplified by PCR using PfuTurbo DNA
polymerase (Stratagene, La Jolla, CA, USA) and the set of
sense and antisense primers. Subsequently, the PCR
products were cloned in the expression vector pcDNA4/
HisMax-TOPO (Invitrogen) to express a fusion protein
with an N-terminal Xpress tag. The vectors were trans-
fected in HEK293 cells using Lipofectamine 2000 reagent
(Invitrogen) for transient expression.
Western blot analysis
To prepare the total protein extract, cultured cells and fro-
zen brain tissues were homogenized in RIPA buffer
(Sigma) supplemented with a cocktail of protease inhibi-
tors (Sigma), followed by centrifugation at 12,000 rpm for
10 minutes at room temperature to harvest the superna-
tant. The protein was separated on a 12% SDS-PAGE gel.
After gel electrophoresis, the protein was transferred onto
nitrocellulose membranes, followed by incubation at room
temperature overnight with the anti-C9orf72 antibody
sc-138763 or HPA023873. The membranes were then
incubated at room temperature for 30 minutes with horse-
radish peroxidase-conjugated anti-rabbit IgG (Santa Cruz
Biotechnology). The specific reaction was visualized by
exposing the membranes to a chemiluminescent substrate
(Pierce, Rockford, IL, USA). After the antibodies were
stripped by incubating the membranes at 50°C for 30 min-
utes in stripping buffer, composed of 62.5 mM Tris-HCl,
pH 6.7, 2% SDS and 100 mM 2-mercaptoethanol, the
membranes were processed for relabeling with anti-GFAP
antibody (GA5; Nichrei) or anti-heat shock protein Hsp60
antibody (sc-1052; Santa Cruz Biotechnology), which
serves as an internal control of protein loading.
To prepare the total protein extract for two-dimensional
gel electrophoretic analysis, the cells were homogenized in
rehydration buffer composed of 8 M urea, 2% CHAPS,
0.5% carrier ampholytes pH 3 to 10, 20 mM dithiothreitol,
0.002% bromophenol blue, and a cocktail of protease inhi-
bitors. Urea-soluble protein was separated by isoelectric
focusing using the ZOOM IPGRunner system loaded with
an immobilized pH 3 to 10 gradient strip (Invitrogen).
After the first dimension of isoelectric focusing, the pro-
tein was separated in the second dimension on a 4 to 12%
NuPAGE polyacrylamide gel (Invitrogen). The gel was
then transferred onto a polyvinylidene difluoride mem-
brane for western blot analysis.
Statistical analysis
The signal intensity of C9orf72-immunopositive bands
was quantified using ImageJ software (National Institute of
Health, Bethesda, MD, USA), and was standardized indivi-
dually by the signal intensity of Hsp60. The lysignificant
difference between groups was evaluated by Student’s
t test. The correlation between GFAP and HSP023873 sig-
nals of individual cases was evaluated by Pearson’s correla-
tion coefficient test.
Results
Universal expression of C9orf72 mRNA in human neural
cells
The human C9orf72 gene encodes three distinct tran-
scripts that produce two alternative isoforms. Transcript
variants 3 [GenBank:NM_001256054] and 2 [GenBank:
NM_018325] express a 481 amino acid protein encoded
by exons 2 to 11 termed isoform a, while transcript variant
1 [GenBank:NM_145005] codes for a 222 amino acid pro-
tein encoded by exons 2 to 5 termed isoform b. Using
RT-PCR, all of the cells and tissues - including the human
cerebrum, astrocytes, neuronal progenitor cells, NTera2
teratocarcinoma-derived neurons, SK-N-SH neuroblas-
toma, IMR-32 neuroblastoma, U-373MG glioblastoma,
HMO6 microglia, and peripheral blood mononuclear cells
- expressed both isoforms (Figure 1a,b, lanes 2 to 10). The
levels of G3PDH, a housekeeping gene, were almost con-
stant in the cells and tissues examined (Figure 1c, lanes 2
to 10). No products were amplified when the reverse tran-
scription step was omitted (Figure 1a to 1c, lane 1). The
expression of mRNA coding for both isoforms a and b of
C9orf72 is thus universal in human neural cells and per-
ipheral blood mononuclear cells.
Characterization of anti-C9orf72 antibodies
Before starting immunohistochemical studies, the speci-
ficity of two rabbit anti-human C9orf72 antibodies
named sc-138763 and HPA023873 was verified by wes-
tern blot analysis of the recombinant C9orf72 protein
expressed in HEK293 cells. Both antibodies recognized a
58 kDa recombinant C9orf72 protein tagged with
Xpress, in addition to a 54 kDa endogenous C9orf72
protein (Figure 2a, lanes 1 to 3). The bands of endogen-
ous C9orf72 detected by HPA023873 were more intense
than those labeled by sc-138763. In preliminary experi-
ments, we found that HPA023873 but not sc-13873
stains intensely reactive astrocytes surrounding ischemic
lesions in the brains of cerebral infarction by immuno-
histochemistry (data not shown). The reactivity of
HPA023873 to GFAP was therefore determined by
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Figure 1 Universal expression of C9orf72 mRNA in human neural cells. Expression of the chromosome 9 open reading frame 72 (C9orf72)
transcript encoding isoform a or isoform b was studied by RT-PCR in human tissues and cultured cells. (a) Isoform a. (b) Isoform b. (c) G3PDH, a
housekeeping gene for a positive control. Lane 1, frontal cortex of the human cerebrum (CBR) without inclusion of the reverse transcription step;
lane 2, CBR with inclusion of the reverse transcription step; lane 3, astrocytes (AS); lane 4, neuronal progenitor (NP) cells; lane 5, NTera2
teratocarcinoma-derived neurons; lane 6, SK-N-SH neuroblastoma; lane 7, IMR-32 neuroblastoma; lane 8, U-373MG glioblastoma; lane 9, HMO6
microglia; lane 10, peripheral blood mononuclear cells (PBMC).
Figure 2 Characterization of anti-C9orf72 antibodies. Full-length ORF of the human chromosome 9 open reading frame 72 (C9orf72) gene
or the human glial fibrillary acidic protein (GFAP) gene, cloned in the vector that expresses a fusion protein with an N-terminal Xpress tag, was
transiently expressed in HEK293 cells. Total protein extract was processed for separation on one-dimensional (1D) or two-dimensional (2D) SDS-
PAGE, followed by western blot analysis. (a) 1D, C9orf72 labeled by HPA023873 (left) or sc-138763 (right). (b) 1D, GFAP. (c) 1D, Hsp60, an internal
control for protein loading. (d) 2D of the recombinant GFAP protein, HPA023873. (e) 2D identical to (d), GFAP. Lane 1, nontransfected cells; lane
2, cells transfected with the vector expressing GFAP; lane 3, cells transfected with the vector expressing C9orf72. (f) A cross-reactive epitope
between C9orf72 and GFAP recognized by HPA023873 aligned by the ClustalW program.
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western blot analysis of the recombinant GFAP protein
expressed in HEK293 cells. HPA023873 but not sc-138763
reacted with a 56 kDa GFAP protein tagged with Xpress
(Figure 2a,b, lane 2; position of recombinant GFAP indi-
cated by the arrow). The cross-reactivity of HPA023873 to
GFAP was further determined by separation on two-
dimensional SDS-PAGE of the recombinant GFAP pro-
tein, followed by western blot analysis (Figure 2d,e). These
results indicated that both sc-138763 and HPA023873
antibodies reacted well with C9orf72, although the latter
showed a substantial cross-reactivity to GFAP. The align-
ment of C9orf72 and GFAP amino acid sequences on
ClustalW analysis [26] suggested the presence of a discon-
tinuous epitope possibly responsible for the cross-reactiv-
ity within the immunogenic peptide of HPA023873 but
not that of sc-138763 (Figure 2f).
Western blot analysis of C9orf72 expression in human
brain homogenates
Next, C9orf72 protein expression was studied in the fro-
zen human frontal cortex tissues by western blot analysis.
Both antibodies reacted well with a 54 kDa protein that
corresponds to isoform a, expressed at variable levels
among the brains of AD, ALS and PD patients and neu-
rologically normal subjects (Figure 3a,b, lanes 1 to 21).
We did not find expression of a 25 kDa protein corre-
sponding to isoform b in any cases examined. The sc-
138763 antibody reacted occasionally with a 58 kDa
uncharacterized protein (Figure 3a, lanes 4 and 11).
Furthermore, HPA023873 often labeled additional bands
with molecular weight ranging from approximately 48 to
38 kDa (Figure 3b, lanes 1 to 3, 5, 6, 18 and 21). All of
the brains expressed multiple GFAP isoforms with vary-
ing intensities (Figure 3c, lanes 1 to 21). By quantitative
analysis, the levels of expression of sc-138763-immunor-
eactive bands were not different between AD and non-
AD cases (Figure 4a), suggesting that the interindividual
variation of sc-138763 immunoreactive bands is probably
not disease specific. In contrast, the levels of expression
of the bands immunopositive for HSP023873 and GFAP
were elevated significantly in AD brains, compared with
non-AD brains (Figure 4b and 4c). Notably, there existed
a positive correlation between the levels of GFAP and
those of HSP023873 in individual cases (r = 0.691, P =
0.0005) (Figure 4d), consistent with the observation that
HPA023873 exhibits cross-reactivity to GFAP.
Immunohistochemical characterization of C9orf72
expression in AD and non-AD brains
Finally, expression of C9orf72 was studied in the frontal
cortex and the hippocampus of six AD patients and 13
non-AD cases by immunohistochemistry. The sc-138763
antibody stained the cell bodies of neurons and oligoden-
drocytes, labeled with variable intensities in both AD and
non-AD brains (Figures 5a,b and 6a). The neuronal and
oligodendroglial nuclei were always devoid of sc-138763
Figure 3 C9orf72 expression in Alzheimer’s disease and non-Alzheimer’s disease brains by western blot analysis. Expression of
chromosome 9 open reading frame 72 (C9orf72) protein studied in the frozen frontal cortex tissues by western blot analysis. Total protein
extract of 15 μg was loaded on each lane. (a) sc-138763. (b) HPA023873. (c) Glial fibrillary acidic protein (GFAP). (d) Hsp60, an internal control for
protein loading. Lanes 1 to 7, brains derived from Alzheimer’s disease (AD) patients; lanes 8 to 11, brains derived from normal control subjects
(non-neurological cause (NC)); lanes 12 to 17, brains derived from amyotrophic lateral sclerosis (ALS) patients; and lanes 18 to 21, brains derived
from Parkinson’s disease (PD) patients (see Table 1). The position of the molecular weight marker is indicated on the left.
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immunoreactivity. The neuropils in the hippocampus
CA2 and CA3 regions frequently showed a coarse punc-
tuate sc-138763 immunoreactivity suggestive of location
at synaptic terminals in both AD and non-AD brains
(Figure 6b). In contrast, sc-138763 did not react with
astrocytes or microglia in any brains examined. Notably,
the sc-138763 antibody intensely labeled a cluster of
focally swollen, dystrophic neurites with irregular-shaped
stick-like and rugby ball-like morphologies, which were
mostly distributed in the CA1 region and the molecular
layer in the hippocampus of AD, ALS, PD, MSA, and nor-
mal control brains (Figures 6c and 7a,c). Most notably, sc-
138763 reacted strongly with dot-like, button-like and
string-like dystrophic neurites positive for PHF-tau (AT8)
accumulated on senile plaques (Figures 7b and 8b).
The HPA023873 antibody stained the cell bodies of neu-
rons and reactive astrocytes, and the neuropil, labeled with
variable intensities, but labeled neither oligodendrocytes
nor microglia, in both AD and non-AD brains (Figure 6d).
Most notably, HPA023873 intensely stained not all but
considerable numbers of senile plaques with or without
accumulation of dystrophic neurites, and surrounding
astrocytes in AD brains (Figures 5c,d, 7d and 8a). In con-
trast, HPA023873 reacted barely with swollen dystrophic
neurites recognized by sc-138763 distributed in the CA1
region and the molecular layer of the hippocampus in AD
and non-AD brains. By double immunolabeling or single
labeling of the serial sections, swollen dystrophic neurites
labeled by sc-138763 were mostly negative for p62, ubiqui-
tin, UBQLN2, phospho-TDP-43 and PHF-tau, but positive
for UBQLN1 (Figure 8c to f). Furthermore, both sc-
138763 and HPA023873 antibodies did not stain any type
of cytoplasmic and nuclear inclusions in neurons and glial
cells if they exist in AD and non-AD brains. We detected
no cross-reactivity of anti-UBQLN1 (sc-14652) antibody
and anti-PHF-tau (AT8) antibody to GFAP by western
blot (data not shown).
Discussion
The human C9orf72 gene encodes a 54 kDa protein with
unknown function, expressed at high levels in the CNS.
Previous studies by immunohistochemistry with two dif-
ferent anti-C9orf72 antibodies named sc-138763 and
HPA023873 showed that C9orf72 is expressed chiefly in
the cytoplasm of neurons, and is highly concentrated in
the synaptic terminals in the brains of FTD/ALS with or
without C9orf72 repeat expansion as well as those of con-
trols [1,5-7,9,15]. In addition, these antibodies did not
react with any intracellular inclusions except for Pick
bodies in the disease-affected brains [1-3,5-7,9,15]. Finally,
a recent study concluded that C9orf72 immunolabeling of
FTD, ALS, AD, and control brains with HPA023873 could
not identify the disease-specific pathology [27].
In the present study, we found by RT-PCR that the
transcripts encoding C9orf72 isoforms a and b are
expressed widely in human neural cells. We characterized
the specificity of sc-138763 and HPA023873 antibodies,
and found that both antibodies react well with C9orf72 -
but HPA023873 exhibits a substantial cross-reactivity to
GFAP, and therefore intensely stains reactive astrocytes
in both AD and non-AD brains. The sc-138763 antibody
was raised against the peptide mapping within amino
acid residues 165 to 215 of C9orf72, while HPA023873
was directed to residues 110 to 199 containing the GFAP
cross-reactive epitope spanning residues 112 to 155
(Figure 2f). Currently, another two rabbit anti-C90rf72
antibodies are commercially available: GTX119776 direc-
ted to residues 1 to 198 (GeneTex, Irvine, CA, USA) and
22637-1-AP directed to residues 1 to 169 (ProteinTech,
Chicago, IL 60612, USA), both of which share the puta-
tive GFAP cross-reactive epitope.
By western blot analysis we identified the expression of
C9orf72 protein in the brains of AD, ALS, and PD patients
and normal subjects, with the levels of expression showing
a possibly disease-nonspecific interindividual variation,
although we have not yet attempted to determine C9orf72
mutations in any cases examined. However, a recent
nationwide study showed that C9orf72 mutations are
Figure 4 Quantification of C9orf72 expression levels in
Alzheimer’s disease and non-Alzheimer’s disease brains.
Expression of chromosome 9 open reading frame 72 (C9orf72)
protein studied in the frozen frontal cortex tissues of seven
Alzheimer’s disease (AD) and 14 non-AD cases by western blot
analysis as shown in Figure 3. Signal intensity of all immunopositive
bands combined was quantified using ImageJ software, and was
standardized individually by the signal intensity of Hsp60. Signal
intensity ratio: (a) sc-138763/Hsp60, (b) HPA023873/Hsp60, and
(c) glial fibrillary acidic protein (GFAP)/Hsp60. (d) Correlation between
the GFAP/Hsp60 and HPA023873/Hsp60 ratios in individual cases.
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extremely rare in Japanese familial and sporadic ALS
patients, where two patients out of a total 563 ALS
patients (0.4%) exhibited the C9orf72 repeat expansion
[18]. By immunohistochemistry we found that both anti-
bodies stained the neuronal cytoplasm and the neuropil
labeled with variable intensities. Furthermore, antibodies,
much more intensely sc-138763, labeled a cluster of p62-
negative, UBQLN1-positive swollen dystrophic neurites
distributed in the CA1 region and the molecular layer in
the hippocampus of both AD and non-AD brains. Most
notably, both sc-138763 and HPA023873 antibodies
reacted strongly with not all but substantial numbers of
dystrophic neurites accumulated on senile plaques in AD
brains. These observations suggest a general role of
C9orf72 in the process of neurodegeneration in a range of
human neurodegenerative diseases.
Using anti-UBQLN2 antibodies named 5F5 (Abnova,
Walnut, CA, USA) and AP12092PU-N (Acris, San
Diego, CA, USA), a recent study showed that numer-
ous immunopositive aggregates and dystrophic neurites
are accumulated in the hippocampal molecular layer
and CA1-CA4 regions in the brains of FTLD/ALS
patients with C9orf72 expansion, whereas the brains of
the cases without the expansion barely show these
structures [27]. However, both of these antibodies are
generated against the peptides, whose amino acid
sequences are shared mostly between UBQLN1 and
UBQLN2. These antibodies therefore could not discri-
minate immunoreactivities between UBQLN1 and
UBQLN2. In contrast, we utilized anti-UBQLN1 anti-
body sc-14652 and anti-UBQLN2 antibody sc-14658,
whose specificities were individually validated by wes-
tern blot analysis of the corresponding recombinant
proteins expressed in HEK293 cells. We verified that
sc-14652 does not label UBQLN2, whereas sc-14658
does not react with UBQLN1.
Figure 5 C9orf72 immunoreactivity in the frontal cortex of Alzheimer’s disease brains. Expression of chromosome 9 open reading frame
72 (C9orf72) studied in the frontal cortex of Alzheimer’s disease brains by immunohistochemistry using sc-138763 and HPA023873 antibodies. (a)
sc-138763, neurons and the neuropil. (b) HPA023873, neurons, the neuropil, and senile plaques (arrows). (c) HPA023873, senile plaque and
surrounding astrocytes. (d) HPA023873, perivascular plaques with reactive astrocytes.
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Increasing evidence indicates that both UBQLN1 and
UBQLN2 play a central role in the ubiquitin/proteasome
system that degrades short-lived and misfolded ubiquti-
nated proteins, while p62 acts mainly as a cargo receptor
for selective autophagy that degrades larger structures,
including protein aggregates or entire organelles [28,29].
p62 is found to be co-localized with ubiquitin in neuronal
and glial inclusions in AD, PD, and MSA brains [30]. In
contrast, we did not identify C9orf72-immunopositive
neuronal and glial inclusions in any brains examined.
UBQLN1, by acting as an interactor for presenilin-1 and
presenilin-2, promotes accumulation of presenilin pro-
teins [31]. Missense mutations in the UBQLN2 gene are
identified in some cases of dominantly inherited, chro-
mosome-X-linked ALS with dementia [32]. In the pre-
sent study using the ubiquilin class-specific antibodies,
focally swollen, dystrophic neurites distributed in the
CA1 region and the molecular layer in the hippocampus
of both AD and non-AD brains express both UBQLN1
and C9orf72, but they do not express phospho-TDP-43,
p62 or UBQLN2, suggesting the possibility that C9orf72
concentrated in dystrophic neurites plays a key role in
the homeostasis of protein degradation, by acting in
cooperation with UBQLN1.
Conclusion
C9orf72 is expressed in dystrophic neurites accumulated
on senile plaques in AD brains, and in swollen dystrophic
neurites distributed in the CA1 region and the molecular
layer in the hippocampus of AD, ALS, PD, MSA, and
normal control brains. These results suggest a more gen-
eral role for C9orf72 in the process of neurodegeneration
in various human neurodegenerative diseases. This view
should be further evaluated by studies on large-scale
Figure 6 C9orf72 immunoreactivity in the hippocampus of non-Alzheimer’s disease brains. Expression of chromosome 9 open reading
frame 72 (C9orf72) studied in the hippocampus of non-Alzheimer’s disease brains by immunohistochemistry using sc-138763 and HPA023873
antibodies. (a) sc-138763, Parkinson’s disease (PD), oligodendrocytes in the white matter. (b) sc-138763, normal subject, synaptic terminals in the
neuropil of CA2. (c) sc-138763, PD, swollen dystrophic neurites with stick and rugby ball shapes in the molecular layer. (d) HPA023873, PD,
reactive astrocytes in the periventricular white matter.
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Figure 7 C9orf72 immunoreactivity in the hippocampus of Alzheimer’s disease brains. Expression of chromosome 9 open reading frame
72 (C9orf72) studied in the hippocampus of Alzheimer’s disease brains by immunohistochemistry using sc-138763 and HPA023873 antibodies.
(a) sc-138763, CA1 overview. (b) sc-138763, CA1, dystrophic neurites accumulated on senile plaque. (c) sc-138763, CA1, dystrophic neurites with
stick and rugby ball shapes. (d) HPA023873, CA4, dystrophic neurites accumulated on senile plaques.
Figure 8 C9orf72, amyloid beta, PHF-tau, p62, UBQLN1, and UBQLN2 immunoreactivities in Alzheimer’s disease and non-Alzheimer’s
disease. Expression of chromosome 9 open reading frame 72 (C9orf72), amyloid beta (Ab), PHF-tau, p62, ubiquilin (UBQLN)1, and UBQLN2
studied in the hippocampus of Alzheimer’s disease (AD) and non-AD brains by double immunolabeling or single labeling of the serial sections.
(a) HPA023873 (brown) and red (Ab), AD, CA4, C9orf72-positive dystrophic neurites on amyloid plaques. (b) sc-138763 (brown) and AT8 (red),
AD, C9orf72-positive PHF-tau-positive dystrophic neurites on senile plaques on the molecular layer. (c) sc-138763 (brown) and p62 (red), multiple
system atrophy (MSA), C9orf72-positive p62-negative swollen dystrophic neurites in the molecular layer. (d) sc-138763 single labeling, MSA,
C9orf72-positive swollen dystrophic neurites in the molecular layer. (e) UBQLN1 single labeling, MSA, area identical to (d), swollen dystrophic
neurites positive for UBQLN1. (f) UBQLN2 single labeling, MSA, area identical to (d), swollen dystrophic neurites negative for UBQLN2.
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samples of AD and other neurodegenerative diseases with
highly specific antibodies.
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